|
CN103764669A
|
|
Anti-inflammatory pharmaceutical products
|
|
AU2012200936A1
|
|
Improved bacterial host cell for the direct expression of peptides
|
|
WO2012040364A1
|
|
Calcitonin products and therapies for treating inflammatory or degenerative diseases
|
|
US2010256060A1
|
|
Peptide pharmaceuticals for nasal delivery
|
|
KR20110119707A
|
|
Treatment for obesity
|
|
US2009317462A1
|
|
Peptide pharmaceutical for oral delivery
|
|
WO2008133618A1
|
|
Methods and compositions for fostering and preserving bone growth
|
|
US2007254328A1
|
|
Glyoxylate assays and their use of inden tifying natural amidated compounds
|
|
EP1907561A2
|
|
Cell lines for expressing enzyme useful in the preparation of amidated products
|
|
CN101222881A
|
|
Bone implant device
|
|
US2006127995A1
|
|
Enzymatic reactions in the presence of keto acids
|
|
WO2006124062A1
|
|
Method for fostering bone formation and preservation
|
|
US2006094656A1
|
|
Method for fostering bone formation and preservation
|
|
CN101052410A
|
|
Method for fostering bone formation and preservation
|
|
US2005256047A1
|
|
Method for fostering bone formation and preservation
|
|
EP1758927A2
|
|
Amidated parathyroid hormone fragments and uses thereof
|
|
CN1738606A
|
|
Improved oral delivery of peptides
|
|
US2003017203A1
|
|
Oral peptide pharmaceutical dosage form and method of production
|
|
AU1567902A
|
|
Direct expression of peptides into culture media
|
|
US2003118610A1
|
|
Oral delivery of peptides using enzyme-cleavable membrane translocators
|
